There are two basic delivery choices for psoriasis medications, says Kenneth Gordon, Professor of Dermatology at Northwestern University. While biologic therapies given as shots have higher response rates, new oral medications such as apremilast and tofacitinib work well, cost less, and may appeal to patients who don’t like injectibles.
More like this
- Apremilast Offers a Strong Oral Choice for Psoriatic Arthritis Patients
- A Phase II Trial Finds Ixekizumab “Extremely Effective” and Safe for Psoriasis
- Where do new diabetes treatments fit in?
- Employers are looking more closely at outcomes
- Costly biologics have plan sponsors looking at benefit designs
